Normal myocardial metabolism: Fueling cardiac contraction

Advanced Studies in Medicine

Volumn 4, Issue 6 B, 2004, Pages

  Weiss, Robert G ^a,b   Maslov, Mikhail ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; CARBOHYDRATE; FATTY ACID; KETONE;

CITRIC ACID CYCLE; ENERGY EXPENDITURE; ENZYME SUBSTRATE; FATTY ACID OXIDATION; GLYCOLYSIS; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; OXIDATION; OXYGENATION; REVIEW;

EID: 4143141879     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Lipmann F. Metabolic generation and utilization of phosphate bond energy. Adv Enzymology. 1941;1:99-162.
2. Krebs HA, Kornberg HL. Energy Transformations in Living Matter. Berlin: Springer-Verlag; 1957:213-298.
3. Saks VA, Ventura-Clapier R, Leverve X, Rossi A, Rigoulet M. What do we not know of cellular bioenergetics? A general view on the state of the art. Mol Cell Biochem. 1998;184(1-2):3-9.
4. Ingwall JS. Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol. 1982;242(5):H729-H744.
5. Ingwall JS, Kramer MF, Fifer MA, et al. The creatine kinase system in normal and diseased human myocardium. N Engl J Med. 1985;313(17):1050-1054.
6. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med. 1990;323(23):1593-1600.
7. Wallimann T, Dolder M, Schlattner U, et al. Some new aspects of creatine kinase (CK): compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. Biofactors. 1998;8(3-4):229-234.
8. Wallimann T. Bioenergetics. Dissecting the role of creatine kinase. Curr Biol. 1994;4(1):42-46.
9. Campbell FM, Kozak R, Wagner A, et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 2002;277(6):4098-4103.
10. Aoyama T, Peters JM, Iritani N, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferators-activated receptor alpha (PPARalpha). J Biol Chem. 1998;273(10):5678-5684.
11. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA. 1994;91(23):11012-11016.
12. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 3rd ed. New York: Worth Publishers; 2000.
13. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature. 1995;377(6545): 151-155.
14. Olson AL, Pessin JE. Structure, function and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr. 1996;16:235-256.
15. Kobayashi K, Neely JR. Control of maximum rates of glycolysis in rat cardiac muscle. Circ Res. 1979;44(2):166-175.
16. Neely JR, Whitfield CF, Morgan HE. Regulation of glycogenolysis in hearts: effects of pressure development, glucose, and FFA. Am J Physiol. 1970;219(4):1083-1088.
17. Runnman EM, Lamp ST, Weiss JN. Enhanced utilization of exogenous glucose improves cardiac function in hypoxic rabbit ventricle without increasing total glycolytic flux. J Clin Invest. 1990;86(4):1222-1233.
18. Entman ML, Bornet EP, Garber AJ, et al. The cardiac sarcoplasmic reticulum-glycogenolytic complex. A possible effector site for cyclic AMP. Biochim Biophys Acta. 1977;499(2):228-237.
19. Weiss RG, Chacko VP, Gerstenblith G. Fatty acid regulation of glucose metabolism in the intact beating rat heart assessed by carbon-13 NMR spectroscopy: the critical role of pyruvate dehydrogenase. J Mol Cell Cardiol. 1989;21(5):469-478.
20. Patel TB, Olson MS. Regulation of pyruvate dehydrogenase complex in ischemic rat heart. Am J Physiol. 1984;246(6, pt 2):H858-H864.
21. Kerbey AL, Rondle PJ, Cooper RH, Whitehouse S, Pask HT, Denton RM. Regulation of pyruvate dehydrogenase in rat heart. Mechanism of regulation of proportions of dephosphorylated and phosphorylated enzyme by oxidation of fatty acids and ketone bodies and of effects of diabetes: role of coenzyme A, acetyl-coenzyme A and reduced and oxidized nicotinamide-adenine dinucleotide. Biochem J. 1976;154(2):327-348.
22. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev. 2002;7(2):115-130.
23. Wieland O, Siess E, Schulze-Wethmar FH, von Funcke HG, Winton B. Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney: effect of diabetes, fasting, and refeeding on pyruvate dehydrogenase interconversion. Arch Biochem Biophys. 1971;143(2):593-601.
24. Mitchell P, Moyle J. Chemiosmotic hypothesis of oxidative phosphorylation. Nature. 1967;213(72):137-139.
25. Dzeja PP, Terzic A. Phosphotransfer networks and cellular energetics. J Exp Biol. 2003;206(pt 12):2039-2047.
26. Kaasik A, Veksler V, Boehm E, Novotova M, Ventura-Clapier R. From energy store to energy flux: a study in creatine kinase-deficient fast skeletal muscle. FASEB J. 2003;17(6):708-710.
27. Joubert F, Mazet JL, Mateo P, Hoerter JA. 31P NMR detection of subcellular creatine kinase fluxes in the perfused rat heart: contractility modifies energy transfer pathways. J Biol Chem. 2002;2779(21):18469-18476.
28. Gibbs C. The cytoplasmic phosphorylation potential. Its possible role in the control of myocardial respiration and cardiac contractility. J Mol Cell Cardiol. 1985;17(8): 727-731.
29. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213(3):263-276.
30. Rovetto MJ, Lamberton WF, Neely JR. Mechanisms of glycolytic inhibition in ischemic rat hearts. Circ Res. 1975;37(6):742-751.
31. Kobayashi K, Neely JR. Control of maximum rates of glycolysis in rat cardiac muscle. Circ Res. 1979;44(2):166-175.
32. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997;33(2): 243-257.
33. Stanley WC, Hernandez LA, Spires D, Bringas J, Wallace S, McCormack JG. Pyruvate dehydrogenase activity and malonyl CoA levels in normal and ischemic swine myocardium: effects of dichloroacetate. J Mol Cell Cardiol. 1996;28(5):905-914.
34. Awan MM, Saggerson ED. Malonyl-CoA metabolism in cardiac myocytes and its relevance to the control of fatty acid oxidation. Biochem J. 1993;295(pt 1):61-66.
35. Kruszynska YT, McCormack JG, McIntyre N. Effects of glycogen stores and non-esterified fatty acid availability on insulin-stimulated glucose metabolism and tissue pyruvate dehydrogenase activity in the rat. Diabetologia. 1991;34(4):205-211.
36. Jafri MS, Dudycha SJ, O'Rourke B. Cardiac energy metabolism: models of cellular respiration. Annu Rev Biomed Eng. 2001;3:57-81.
37. Cortassa S, Aon MA, Marban E, Winslow RL, O'Rourke B. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J. 2003;84(4):2734-2755.
38. Wisneski JA, Stanley WC, Neese RA, Gertz EW. Effects of acute hyperglycemia on myocardial glycolytic activity in humans. J Clin Invest. 1990;85(5):1648-1656.
39. Starling RC, Hammer DF, Altschuld RA. Human myocardial ATP content and in vivo contractile function. Mol Cell Biochem. 1998;180(1-2):171-177.
40. Tillisch JH, Brunken R, Marshall RC, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314(14):884-888.
41. Buxton DB, Schwaiger M, Nguyen A, Phelps ME, Schelbert HR. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circ Res. 1988;63(3):628-634.
42. Sun KT, Yeatman LA, Buxton DB, et al. Simultaneous measurement of myocordial oxygen consumption and blood flow using [1-carbon 11] acetate. J Nucl Med. 1998;39(2):272-280.
43. Bottomley PA, Atalar E, Weiss RG. Human cardiac high-energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn Reson Med. 1996;35(5):664-670.
44. Beer M, Seyfarth T, Sandstede J, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267-1274.
45. Bottomley PA, Weiss RG. Non-invasive magnetic-resonance defection of creatine depletion in non-viable infarcted myocardium. Lancet. 1998;351(9104):714-718.
46. Buchthal SD, Den Hollander JA, Merz C, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med. 2000;342(12):829-835.
47. Neubauer S, Krahe T, Schindler R, et al. 31P Magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86(6):1810-1818.